How have ELYM shares performed in 2024?

Eliem Therapeutics' stock was trading at $2.70 on January 1st, 2024. Since then, ELYM shares have increased by 54.8% and is now trading at $4.18. View the best growth stocks for 2024 here .

When is Eliem Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our ELYM earnings forecast .

How were Eliem Therapeutics' earnings last quarter?

Eliem Therapeutics, Inc. (NASDAQ:ELYM) released its quarterly earnings results on Monday, November, 8th. The company reported ($0.70) earnings per share for the quarter, topping the consensus estimate of ($0.89) by $0.19.

When did Eliem Therapeutics IPO?

Eliem Therapeutics (ELYM) raised $75 million in an IPO on Tuesday, August 10th 2021. The company issued 6,000,000 shares at a price of $12.50 per share. SVB Leerink, Evercore ISI, Stifel and Guggenheim Securities served as the underwriters for the IPO.

How do I buy shares of Eliem Therapeutics?

Shares of ELYM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ELYM

Eliem Therapeutics (ELYM) Stock Price, News & Analysis

→ AI “wealth window” is closing soon! (From Paradigm Press) (Ad)

Free ELYM Stock Alerts

$4.18

-0.25 (-5.64%)

(As of 04/18/2024 ET)

Compare

Today's Range: $4.15
▼
$4.50
50-Day Range: $2.54
▼
$4.75
52-Week Range: $2.34
▼
$5.19

Volume: 208,796 shs
Average Volume: 591,608 shs
Market Capitalization: $115.87 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get Eliem Therapeutics alerts:

Ad Insiders Exposed

This consistently signaled gains of 453%... 610%... and even 1036%...

It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.

About Eliem Therapeutics Stock (NASDAQ:ELYM)

Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its lead drug candidate is ETX-123, a Kv7.2/3 potassium channel opener, which is in preclinical for the treatment of neuronal excitability disorders, such as epilepsy, pain, depression, and others; and ETX-155 for the treatment of major depressive disorder and focal onset seizures that is in Phase 2a clinical trial. The company was incorporated in 2018 and is headquartered in Redmond, Washington.

ELYM Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ELYM Stock News Headlines

April 15, 2024 | prnewswire.com

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Eliem Therapeutics, Inc. (ELYM) and Encourages Investors to Contact the Firm

April 12, 2024 | finanznachrichten.de

Eliem Therapeutics, Inc.: Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement

April 18, 2024 | Darwin (Ad)

Explore the Future: Unlock the Top 3 AI Stocks for 2024 Report

Eager to enhance your investment strategies with foresight? Dive into our intriguing report: "The Top 3 AI Stocks for 2024." Gain profound insights and uncover the secrets with just a click! Why This Report Is Your Gateway to Success: * Expertly Curated: Delve into the AI stocks handpicked by our market analysts for 2024's success story. * In-Depth Analysis: Dive deep into comprehensive profiles and explore each top stock. (**By clicking the link you are subscribing to The Wealthiest Investor Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy. Full disclosures found here.)

April 11, 2024 | stockhouse.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALPN, ELYM, MODN

April 11, 2024 | finance.yahoo.com

Eliem Therapeutics Shifts From Neurology With New Found Focus On Autoimmune Diseases With Tenet Medicines Deal

April 11, 2024 | msn.com

Enlivex Therapeutics, Nyxoah SA, China SXT Pharmaceuticals among healthcare movers

April 11, 2024 | markets.businessinsider.com

Eliem Therapeutics To Buy Tenet Medicines, Plans $120 Mln Private Placement; Stock Up In Pre-market

April 11, 2024 | businesswire.com

ELYM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Eliem Therapeutics, Inc. Is Fair to Shareholders

April 18, 2024 | Darwin (Ad)

Explore the Future: Unlock the Top 3 AI Stocks for 2024 Report

April 11, 2024 | globenewswire.com

Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement

April 5, 2024 | msn.com

ELYM Stock Earnings: Eliem Therapeutics Reported Results for Q4 2023

March 6, 2024 | finance.yahoo.com

Here's Why We're Not Too Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Situation

November 19, 2023 | morningstar.com

Checkpoint Therapeutics Inc CKPT

November 15, 2023 | morningstar.com

Eliem Therapeutics Inc ELYM

September 28, 2023 | finance.yahoo.com

Eliem Therapeutics (NASDAQ:ELYM) Is In A Good Position To Deliver On Growth Plans

July 21, 2023 | finance.yahoo.com

Eliem (ELYM) to Explore Strategic Options, Stock Rises 6%

July 21, 2023 | msn.com

Eliem Therapeutics’ stock soars 21% premarket after company says it may sell itself

July 20, 2023 | benzinga.com

What's Happening With Eliem Therapeutics Shares Today?

July 20, 2023 | finanznachrichten.de

Eliem Therapeutics, Inc.: Eliem Therapeutics Announces Plans to Explore Strategic Alternatives

July 20, 2023 | marketwatch.com

Eliem Therapeutics Shares Rally Premarket on Exploration of Options >ELYM

July 20, 2023 | markets.businessinsider.com

Why Is Eliem Therapeutics (ELYM) Stock Up 6% Today?

July 20, 2023 | finance.yahoo.com

Eliem Therapeutics Announces Plans to Explore Strategic Alternatives

June 7, 2023 | markets.businessinsider.com

Stifel Nicolaus Sticks to Its Buy Rating for Eliem Therapeutics (ELYM)

May 25, 2023 | markets.businessinsider.com

Stifel Nicolaus Reaffirms Their Buy Rating on Eliem Therapeutics (ELYM)

May 12, 2023 | finanznachrichten.de

Eliem Therapeutics, Inc.: Eliem Therapeutics Reports First Quarter Financial Results and Business Highlights

May 11, 2023 | seekingalpha.com

Eliem Therapeutics GAAP EPS of -$0.84

May 11, 2023 | finance.yahoo.com

Eliem Therapeutics Reports First Quarter Financial Results and Business Highlights

See More Headlines

Receive ELYM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eliem Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/08/2021
Today: 4/18/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:ELYM
CUSIP: N/A
CIK: 1768446
Web: www.eliemtx.com
Phone: 877-354-3689
Fax: N/A
Employees: 30
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($1.47)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-35,120,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -31.45%
Return on Assets: -30.43%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 38.92
Quick Ratio: 38.92

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.90 per share
Price / Book: 1.07

Miscellaneous

Outstanding Shares: 27,719,000
Free Float: 26,416,000
Market Cap: $115.87 million
Optionable: Not Optionable
Beta: 0.51

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Dr. Andrew Levin M.D. (Age 46)
Ph.D., Principal Financial Officer & Executive Chairman
Comp: $73k
Dr. Valerie Morisset Ph.D. (Age 54)
Chief Scientific Officer and Executive VP of Research & Development
Comp: $617.87k
Ms. Emily Pimblett (Age 40)
Principal Accounting Officer
Ms. Jo Palmer-Phillips Ph.D.
Chief Development Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

ELYM Stock Analysis - Frequently Asked Questions

How have ELYM shares performed in 2024?: Eliem Therapeutics' stock was trading at $2.70 on January 1st, 2024. Since then, ELYM shares have increased by 54.8% and is now trading at $4.18.
View the best growth stocks for 2024 here.
When is Eliem Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our ELYM earnings forecast.
How were Eliem Therapeutics' earnings last quarter?: Eliem Therapeutics, Inc. (NASDAQ:ELYM) released its quarterly earnings results on Monday, November, 8th. The company reported ($0.70) earnings per share for the quarter, topping the consensus estimate of ($0.89) by $0.19.

When did Eliem Therapeutics IPO?: Eliem Therapeutics (ELYM) raised $75 million in an IPO on Tuesday, August 10th 2021. The company issued 6,000,000 shares at a price of $12.50 per share. SVB Leerink, Evercore ISI, Stifel and Guggenheim Securities served as the underwriters for the IPO.
How do I buy shares of Eliem Therapeutics?: Shares of ELYM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ELYM) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial